Home › Transthyretin-Related Hereditary Amyloidosis › District of Columbia
Transthyretin-Related Hereditary Amyloidosis clinical trials in District of Columbia
3 studies for Transthyretin-Related Hereditary Amyloidosis are looking for participants at sites in District of Columbia.
Cities in District of Columbia
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
- Research Site, Washington D.C.
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 23, 2026 · NCT06465810Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- MedStar Washington Hospital Center - MedStar Heart and Vascular Institute, Washington D.C.
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Aug 4, 2026 · NCT06563895MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
- MedStar Washington Hospital Center - MedStar Heart and Vascular Institute, Washington D.C.
RecruitingPhase 3
Ages 18 to 90 · All sexes · Updated Mar 27, 2026 · NCT06128629From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.